PL3837258T3 - Amidy dimetyloaminoazetydyny jako inhibitory jak - Google Patents

Amidy dimetyloaminoazetydyny jako inhibitory jak

Info

Publication number
PL3837258T3
PL3837258T3 PL19769674.3T PL19769674T PL3837258T3 PL 3837258 T3 PL3837258 T3 PL 3837258T3 PL 19769674 T PL19769674 T PL 19769674T PL 3837258 T3 PL3837258 T3 PL 3837258T3
Authority
PL
Poland
Prior art keywords
dimethyl amino
jak inhibitors
amino azetidine
amides
azetidine amides
Prior art date
Application number
PL19769674.3T
Other languages
English (en)
Polish (pl)
Inventor
Daniel D. Long
Cameron Smith
Corbin Thompson
Original Assignee
Theravance Biopharma R&D Ip, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Biopharma R&D Ip, Llc filed Critical Theravance Biopharma R&D Ip, Llc
Publication of PL3837258T3 publication Critical patent/PL3837258T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL19769674.3T 2018-09-04 2019-09-03 Amidy dimetyloaminoazetydyny jako inhibitory jak PL3837258T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862726562P 2018-09-04 2018-09-04
PCT/US2019/049276 WO2020051105A1 (en) 2018-09-04 2019-09-03 Dimethyl amino azetidine amides as jak inhibitors

Publications (1)

Publication Number Publication Date
PL3837258T3 true PL3837258T3 (pl) 2024-09-16

Family

ID=67982186

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19769674.3T PL3837258T3 (pl) 2018-09-04 2019-09-03 Amidy dimetyloaminoazetydyny jako inhibitory jak

Country Status (27)

Country Link
US (4) US10947229B2 (https=)
EP (1) EP3837258B1 (https=)
JP (2) JP7324836B2 (https=)
KR (1) KR102826491B1 (https=)
CN (1) CN112739697B (https=)
AR (1) AR116115A1 (https=)
AU (1) AU2019336167B2 (https=)
BR (1) BR112021004052A2 (https=)
CL (1) CL2021000514A1 (https=)
CO (1) CO2021002977A2 (https=)
DK (1) DK3837258T3 (https=)
EA (1) EA202190681A1 (https=)
ES (1) ES2982858T3 (https=)
FI (1) FI3837258T3 (https=)
HR (1) HRP20241002T1 (https=)
HU (1) HUE068058T2 (https=)
IL (1) IL281146B2 (https=)
LT (1) LT3837258T (https=)
MA (1) MA53229A (https=)
MX (1) MX2021002521A (https=)
PH (1) PH12021550368A1 (https=)
PL (1) PL3837258T3 (https=)
PT (1) PT3837258T (https=)
SG (1) SG11202101734RA (https=)
SI (1) SI3837258T1 (https=)
TW (1) TWI791886B (https=)
WO (1) WO2020051105A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA123633C2 (uk) 2015-11-03 2021-05-05 Тереванс Байофарма Ар Енд Ді Айпі, Елелсі Сполуки інгібітору jak-кінази для лікування респіраторного захворювання
WO2018165392A1 (en) 2017-03-09 2018-09-13 Theravance Biopharma R&D Ip, Llc Jak inhibitors containing a 4-membered heterocyclic amide
JP2021535176A (ja) 2018-09-04 2021-12-16 セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー Jak阻害剤およびその中間体を調製するためのプロセス
FI3837258T3 (fi) * 2018-09-04 2024-05-27 Theravance Biopharma R&D Ip Llc Dimetyyliaminoatsetidiiniamideja jak-estäjinä
UA127328C2 (uk) 2018-09-04 2023-07-19 Тереванс Байофарма Ар Енд Ді Айпі, Елелсі 5-7-членні гетероциклічні аміди як інгібітори jak
TW202144343A (zh) * 2020-03-02 2021-12-01 美商施萬生物製藥研發 Ip有限責任公司 Jak抑制劑化合物之結晶水合物
CN115803023A (zh) * 2020-05-08 2023-03-14 施万生物制药研发Ip有限责任公司 发用奈珠西替尼治疗感染冠状病毒的患者的方法
WO2022271604A1 (en) 2021-06-21 2022-12-29 Theravance Biopharma R&D Ip, Llc Method of treating a patient infected with a coronavirus and having a baseline level of crp below 150 mg/l
EP4359402B1 (en) * 2021-06-25 2026-03-11 Theravance Biopharma R&D IP, LLC Imidazolo indazole compounds as jak inhibitors
KR20230092805A (ko) * 2021-12-17 2023-06-26 주식회사 대웅제약 (2R, 3S)-2-(3-(4,5-디클로로-1H-벤조[d]이미다졸-1-일)프로필)피페리딘-3-올의 신규한 산부가염 및 결정형
US20250288561A1 (en) 2022-05-05 2025-09-18 Theravance Biopharma R&D Ip, Llc Nezulcitinib for delivery by nebulized oral inhalation
WO2023230236A1 (en) 2022-05-26 2023-11-30 Theravance Biopharma R&D Ip, Llc Process for preparing jak inhibitors and intermediates thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
EP1648455A4 (en) 2003-07-23 2009-03-04 Exelixis Inc MODULATORS OF ALK PROTEIN (ANAPLASTIC LYMPHOMA KINASE) AND METHODS OF USE
US20050090529A1 (en) 2003-07-31 2005-04-28 Pfizer Inc 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
US7884109B2 (en) 2005-04-05 2011-02-08 Wyeth Llc Purine and imidazopyridine derivatives for immunosuppression
US8648069B2 (en) 2007-06-08 2014-02-11 Abbvie Inc. 5-substituted indazoles as kinase inhibitors
JP2010111624A (ja) 2008-11-06 2010-05-20 Shionogi & Co Ltd Ttk阻害作用を有するインダゾール誘導体
WO2010114971A1 (en) 2009-04-03 2010-10-07 Sepracor Inc. Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
LT3001903T (lt) 2009-12-21 2018-01-10 Samumed, Llc 1h-pirazolo[3,4-b]piridinai ir jų terapinis panaudojimas
US8575336B2 (en) * 2011-07-27 2013-11-05 Pfizer Limited Indazoles
SI3077395T1 (en) 2013-12-05 2018-03-30 Pfizer Inc. Pyrrolo(2,3-d)pyrimidinyl, pyrrolo(2,3-b)pyrazinyl and pyrrolo(2,3-d)pyridinyl acrylamides
KR20170002623A (ko) 2014-05-14 2017-01-06 화이자 인코포레이티드 피라졸로피리딘 및 피라졸로피리미딘
WO2016026078A1 (en) 2014-08-19 2016-02-25 Changzhou Jiekai Pharmatech Co., Ltd. Heterocyclic compounds as erk inhibitors
KR101663277B1 (ko) 2015-03-30 2016-10-06 주식회사 녹십자 TNIK, IKKε 및 TBK1 억제제로서의 피라졸계 유도체 및 이를 포함하는 약학적 조성물
DK3371185T3 (da) 2015-11-03 2020-11-30 Topivert Pharma Ltd 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridin og 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepinderivater som janus-kinase-inhibitorer
WO2017077283A1 (en) 2015-11-03 2017-05-11 Topivert Pharma Limited 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
UA123633C2 (uk) * 2015-11-03 2021-05-05 Тереванс Байофарма Ар Енд Ді Айпі, Елелсі Сполуки інгібітору jak-кінази для лікування респіраторного захворювання
WO2018165392A1 (en) 2017-03-09 2018-09-13 Theravance Biopharma R&D Ip, Llc Jak inhibitors containing a 4-membered heterocyclic amide
US20180258546A1 (en) 2017-03-09 2018-09-13 Lam Research Corporation Electroplating apparatus and methods utilizing independent control of impinging electrolyte
KR20200003121A (ko) 2017-05-01 2020-01-08 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 Jak 저해제 화합물의 결정형
WO2018204233A1 (en) 2017-05-01 2018-11-08 Theravance Biopharma R&D Ip, Llc Methods of treatment using a jak inhibitor compound
AR111495A1 (es) 2017-05-01 2019-07-17 Theravance Biopharma R&D Ip Llc Compuestos de imidazo-piperidina fusionada como inhibidores de jak
CN112566713A (zh) 2018-07-20 2021-03-26 波里费拉公司 具有再循环回路的渗透模块
UA127328C2 (uk) 2018-09-04 2023-07-19 Тереванс Байофарма Ар Енд Ді Айпі, Елелсі 5-7-членні гетероциклічні аміди як інгібітори jak
FI3837258T3 (fi) 2018-09-04 2024-05-27 Theravance Biopharma R&D Ip Llc Dimetyyliaminoatsetidiiniamideja jak-estäjinä
JP2021535176A (ja) 2018-09-04 2021-12-16 セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー Jak阻害剤およびその中間体を調製するためのプロセス
KR20210084512A (ko) 2018-10-29 2021-07-07 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 Jak 억제제로서 2-아자비시클로 헥산 화합물
HUE067145T2 (hu) 2019-02-25 2024-10-28 Henan Medinno Pharmaceutical Tech Co Ltd JAK inhibitor vegyület és alkalmazása
WO2020181034A1 (en) 2019-03-05 2020-09-10 Incyte Corporation Jak1 pathway inhibitors for the treatment of chronic lung allograft dysfunction
CN112279848A (zh) 2019-07-25 2021-01-29 四川海思科制药有限公司 一种泛JAKs抑制剂及其用途
TW202144343A (zh) * 2020-03-02 2021-12-01 美商施萬生物製藥研發 Ip有限責任公司 Jak抑制劑化合物之結晶水合物
CN115803023A (zh) 2020-05-08 2023-03-14 施万生物制药研发Ip有限责任公司 发用奈珠西替尼治疗感染冠状病毒的患者的方法
WO2022178215A1 (en) 2021-02-19 2022-08-25 Theravance Biopharma R&D Ip, Llc Amino amide tetrahydro imidazo pyridines as jak inhibitors
WO2022204473A1 (en) 2021-03-26 2022-09-29 Theravance Biopharma R&D Ip, Llc Crystalline form of a dihydrochloride salt of a jak inhibitor compound
WO2022271604A1 (en) * 2021-06-21 2022-12-29 Theravance Biopharma R&D Ip, Llc Method of treating a patient infected with a coronavirus and having a baseline level of crp below 150 mg/l

Also Published As

Publication number Publication date
SI3837258T1 (sl) 2024-09-30
US20210155620A1 (en) 2021-05-27
US11634419B2 (en) 2023-04-25
LT3837258T (lt) 2024-05-27
EP3837258B1 (en) 2024-04-24
TWI791886B (zh) 2023-02-11
EA202190681A1 (ru) 2021-05-28
AR116115A1 (es) 2021-03-31
DK3837258T3 (da) 2024-07-22
PT3837258T (pt) 2024-06-20
IL281146B2 (en) 2023-12-01
IL281146B1 (en) 2023-08-01
IL281146A (en) 2021-04-29
US10947229B2 (en) 2021-03-16
MA53229A (fr) 2022-05-11
CL2021000514A1 (es) 2021-07-23
CO2021002977A2 (es) 2021-05-31
HUE068058T2 (hu) 2024-12-28
JP7324836B2 (ja) 2023-08-10
BR112021004052A2 (pt) 2021-05-25
CN112739697B (zh) 2023-10-20
TW202024073A (zh) 2020-07-01
JP2022172299A (ja) 2022-11-15
EP3837258A1 (en) 2021-06-23
KR20210056381A (ko) 2021-05-18
PH12021550368A1 (en) 2022-03-28
MX2021002521A (es) 2021-04-28
AU2019336167A1 (en) 2021-03-11
JP2021535177A (ja) 2021-12-16
US20230322774A1 (en) 2023-10-12
SG11202101734RA (en) 2021-03-30
US20200071323A1 (en) 2020-03-05
HRP20241002T1 (hr) 2024-10-25
US20250034131A1 (en) 2025-01-30
KR102826491B1 (ko) 2025-06-27
US12398135B2 (en) 2025-08-26
AU2019336167B2 (en) 2024-08-29
WO2020051105A1 (en) 2020-03-12
ES2982858T3 (es) 2024-10-17
FI3837258T3 (fi) 2024-05-27
CN112739697A (zh) 2021-04-30

Similar Documents

Publication Publication Date Title
IL281146A (en) Dimethyl amino aztidine amides as JAK inhibitors
IL268625A (en) Amino pyrimidine compounds used as SSAO inhibitors
IL282460A (en) The compound 2-azabicyclohexane as a JAK inhibitor
GB201915593D0 (en) Hand-held integral aribrush
IL287876A (en) Jak inhibitors
IL289266B1 (en) New molecules
IL275374A (en) Pyrrolidine amides I are converted
CA192878S (en) Brush stand
EP3873473A4 (en) Aminoazine amides
IL282676B1 (en) New dipeptide compounds and their uses
GB201708390D0 (en) Novel alpha-amino amide derivatives
IL291611A (en) Jak inhibitors
IL289773A (en) Disubstituted amino triazoles are useful as chitinase inhibitors
GB2601449B (en) Key-compressible encryption
GB201918693D0 (en) Peptide
GB201818629D0 (en) Compositions comprising amino acids
GB201817932D0 (en) Peptide synthesis
IL290381A (en) Jak inhibitors
HK40048449A (en) Dimethyl amino azetidine amides as jak inhibitors
GB201914325D0 (en) Novel meethod
CA190942S (en) Screw head
LT3735823T (lt) Lapų šalintuvo galvutė
ZA202201899B (en) Substituted amino triazoles useful as chitinase inhibitors
GB201912632D0 (en) Peptide
GB201913320D0 (en) Novel proteins